$HGEN News
Last published 4y ago
- 4y agoHGENHumanigen, Inc. Shareholder News: Robbins LLP is Investigating Humanigen, Inc. (HGEN) on Behalf of InvestorsBusiness WireShareholder rights law firm Robbins LLP is investigating Humanigen, Inc. (NASDAQ:HGEN) and its officers and directors to determine whether they breached fiduciary duties and violated securities laws in overstating the clinical and commercial prospects o
- 4y agoHGENMoore Kuehn, PLLC Encourages Investors of Humanigen, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Humanigen, Inc. (NASDAQ:HGEN) breached their fiduciary duties to shareholders. A
- 4y agoCLLSHGENOMGAOmega Therapeutics Announces Appointment of Rainer Boehm to its Board of DirectorsPR NewswireFormer Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass., Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first syst
- 4y agoHGENHumanigen Reports Second Quarter 2022 Financial ResultsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported finan
- 4y agoAQSTDBVTHGENAquestive Therapeutics Strengthens Team to Align with Strategic Focus on Allergy SpaceGlobeNewswireAppoints Timothy E. Morris, a veteran biotech executive with over 35 years of experience in executive and financial leadership, to Board of Directors Names Kenneth Truitt, M.D., with over 25 years of clinical and regulatory experience across biotechnol
- 4y agoHGENHumanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-BBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen") has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir
- 4y agoHGENHumanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive ProteinBusiness WireA sub-analysis of the Phase 3 LIVE-AIR study of lenzilumab showed a strong correlation between C-reactive protein (CRP) and outcomes with lenzilumab treatment with the greatest clinical benefit experienced by patients with baseline CRP<150 mg/L In
- 4y agoHGENNIH/NIAID Locks ACTIV-5/BET-B DatabaseBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, confirms that notice was receive
- 4y agoHGENHumanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United KingdomBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' today announced it entered into an agreement with PCI Pharma Services (PC
- 4y agoHGENHumanigen Announces Participation and Presentation at Multiple Conferences in JuneBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced today that representatives will present and participate at multi
- 4y agoHGENHumanigen Announces Participation and Presentation at H.C. Wainwright Global Investment ConferenceBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced that Cameron Durrant, Chairman & CEO, will give a corporate pres
- 4y agoHGENHumanigen Reports First Quarter 2022 Financial ResultsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate upd
- 4y agoHGENHumanigen Announces Participation and Presentation at Multiple Conferences in MayBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' announced today that management will present and participate at multiple invest
- 4y agoHGENGM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal LeukemiaBusiness WireCRISPR/Cas9-Mediated GM-CSF knock-out (GM-CSFko) CAR-T cells demonstrate reduced apoptosis and enhanced in vivo anti-tumor activity in preclinical models Phase 3 SHIELD study utilizing lenzilumab to prophylactically neutralize GM-CSF in CAR-T to b
- 4y agoHGENHumanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHSBusiness WireIn a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to standard of care (SOC) could result in over £5.5 million in cost savings weekly1 Lenzilumab plus SOC resulted in per‑patient cost savings between £8,462 and £1
- 4y agoBORRGDYNHGENMBII+1Thinking about buying stock in Humanigen, Marrone Bio Innovations, Grid Dynamics, Borr Drilling, or Root?PR NewswireNEW YORK, March 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HGEN, MBII, GDYN, BORR, and ROOT.
- 4y agoHGENHumanigen Reports Year-End 2021 Financial ResultsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab, today reported financial results for the
- 4y agoHGENHumanigen to Present and Participate at Multiple Investor Events in MarchBusiness WireHumanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that management will present and participate at several events in March with
- 4y agoHGENHumanigen to Present at BIO CEO & Investor ConferenceBusiness WireHumanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that Timothy E. Morris, COO/CFO, will be presenting at the upcoming 2022 BIO
- 4y agoHGENHumanigen Launches Managed Access Program for LenzilumabBusiness WireHumanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that lenzilumab is now available for certain hospitalized COVID-19 patients
- 4y agoHGENHumanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in FranceBusiness WireCenexi to Become Preferred Drug Product Supplier for France and the European Union Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine
- 4y agoHGENHumanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of LenzilumabBusiness WireLenzilumab plus standard of care (SOC), resulted in an estimated cost savings of $13,190 per patient (net savings of $3,190, after an assumed price of $10,000 for lenzilumab) in those receiving remdesivir with baseline C-Reactive Protein (CRP) levels
- 4y agoHGENHumanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-TBusiness WireFDA Type C meeting and advice creates alignment on registration pathway for Phase 3 clinical development of lenzilumab for the prevention of CAR-T therapy related toxicities including Immune Effector Cell-Associated Neurotoxicity (ICANS) and Cytokine
- 4y agoHGENHumanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been AchievedBusiness WireTop-line data from ACTIV-5/BET-B expected to be announced late in the first quarter or early in the second quarter of 2022 ACTIV-5/BET-B results to be shared with regulatory authorities in the US, UK, and EU as part of the ongoing review process
- 4y agoHGENHumanigen to Present at Investor Conferences January 7 and 13, 2022Business WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that Cameron Durrant, chairman and chief executive officer of Humani
- 4y agoHGENLenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein LevelsBusiness WireMulti-variate analysis of LIVE-AIR Phase 3 data demonstrates that elevated baseline C-Reactive Protein ("CRP") is the most predictive feature for progression to invasive mechanical ventilation ("IMV") or death and may be a useful biomarker to guide th
- 4y agoHGENHumanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022Business WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that Cameron Durrant, Chairman & CEO, will give a corporate presenta
- 4y agoABUSHGENOMERPHUN+1Thinking about buying stock in Phunware, Omeros Corp, Humanigen, Spirit AeroSystems, or Arbutus Biopharma?PR NewswireNEW YORK, Dec. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PHUN, OMER, HGEN, SPR, and ABUS. T
- 4y agoHGENHumanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate UpdateBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that it will host a conference call and webcast to discuss The Lance
- 4y agoHGENThe Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab ResultsBusiness WireLenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per the paper, the implication from all the available evi
- 4y agoHGENHumanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021Business WireAbstract #S48 describes top-line results from the Humanigen Phase 3 LIVE-AIR study in hospitalized COVID-19 patients, which reveal a 54% relative improvement in the likelihood of survival without invasive mechanical ventilation ("SWOV") in lenzilumab-
- 4y agoHGENHumanigen Announces Revised Time for Presentation at Jefferies London Healthcare ConferenceBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that its presentation time at the Jefferies London Healthcare Confer
- 5y agoHGENHumanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate UpdateBusiness WireHumanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‛cytokine storm' with its lead drug candidate, lenzilumab, today provided a corporate and regulato
- 5y agoHGENHumanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host DiseaseBusiness WireHumanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy in Acute GvHD", or "RATinG", study
- 5y agoHGENHumanigen Announces Release of Abstracts at ASHBusiness WireAbstract #2777 describes preclinical models that demonstrate GM-CSF neutralization with lenzilumab improves CAR-T cell proliferation, but blocking the GM-CSFα receptor may inhibit CAR-T cell proliferation Abstract #1758 describes the Phase 3 SHIE
- 5y agoHGENHumanigen Announces Participation and Presentation at Multiple Conferences in NovemberBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and participate at multiple investors c
- 5y agoHGENFirst Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in Patients with Chronic Myelomonocytic Leukemia (CMML)Business WireEarlier studies have shown the granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing effect of lenzilumab may benefit CMML patients with RAS pathway mutations Study is intended to build on evidence that certain CMML patients have
- 5y agoHGENEuropean Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19Business WireTen most promising treatments for COVID-19 identified by the European Commission's independent experts as having "the highest potential impact on the pandemic"* European Commission's independent panel of 10 experts across Europe created the list a
- 5y agoHGENHumanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM'21Business WireAn abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM‘21 A Phase 1b study of ifabotuzumab in non-CNS solid tum
- 5y agoARAVEVLOGRCLHGEN+1Humanigen Elects John Hohneker, MD, and Kevin Xie, PhD, to Board of DirectorsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced today that the Company's Board of Directors (the "Board") has electe
- 5y agoHGENHumanigen Announces Late-Breaking Presentation at the CHEST Annual Meeting Highlighting C-Reactive Protein as a Biomarker for Identifying Patients Most Likely to Benefit from treatment with LenzilumabBusiness WireBaseline C-reactive Protein (CRP) <150 mg/L identified as the strongest predictor of response to lenzilumab in hospitalized COVID-19 patients In this population age <85 years, lenzilumab improved likelihood of survival without ventilation by 3-fol
- 5y agoHGENHumanigen's Budget Impact Model Demonstrates Lenzilumab's Potential Positive Economic Value in Hospitalized COVID-19 PatientsBusiness WireOverall analysis demonstrates treatment with lenzilumab may result in both clinical and economic benefits in the majority of hospitalized patients Potential clinical and economic benefits are greater in certain patient populations Humanigen,
- 5y agoHGENHumanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in EuropeBusiness WireProgram designed to fulfill requests from healthcare providers for access to lenzilumab, for patients with unmet medical needs Humanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating
- 5y agoHGENHumanigen Announces Participation and Presentation at Multiple Conferences in OctoberBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and participate at multiple virtual inv
- 5y agoHGENHumanigen Submits All Planned Modules for Potential Conditional Marketing Authorization from the UK's MHRABusiness WireHumanigen, Inc. (NASDAQ:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm' with its lead drug candidate, lenzilumab, today announced it has submitted all the planned mo
- 5y agoHGENHumanigen Announces Oral Presentation of Lenzilumab LIVE-AIR Phase 3 Study Results at IDWeek 2021Business WireLenzilumab significantly improved the likelihood of survival without ventilation (SWOV) by 54% versus standard treatment in hospitalized patients with COVID-19 pneumonia IDWeek is the premier global scientific meeting that brings together infectio
- 5y agoHGENHumanigen Announces the European Medicines Agency Has Appointed a Rapporteur and Co-rapporteur as Part of the Process Related to the Planned Submission of a Marketing Authorization Application (MAA) for LenzilumabBusiness WireHumanigen plans to submit an MAA under the centralized procedure seeking Conditional Marketing Authorization (CMA) throughout the European Union (EU) for the use of lenzilumab to treat patients hospitalized with COVID-19 pneumonia Humanigen expect
- 5y agoHGENHumanigen Announces Participation and Presentation at Multiple Conferences in SeptemberBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,' announced that management will present and participate at multiple virtual inv
- 5y agoHGENFDA has declined Humanigen's Emergency Use Authorization (EUA) Request for Lenzilumab in Hospitalized COVID-19 PatientsBusiness WireFDA has committed to working with Humanigen in the development of lenzilumab and has invited Humanigen to submit additional data as it becomes available NIH's ACTIV-5/BET-B study is expected to provide further data that may support a new EUA reque
- 5y agoHGENHumanigen Reports Second Quarter 2021 Financial ResultsBusiness WireHumanigen, Inc. (NASDAQ:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm'" with its lead drug candidate, lenzilumab, today provided a corporate and regulat